Beigene Ltd
NASDAQ:ONC
Operating Margin
Beigene Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KY |
|
Beigene Ltd
SSE:688235
|
216.8B CNY |
-8%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.9B USD |
31%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
157.4B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
146.5B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
99.9B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
113.9B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.1B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.8B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Beigene Ltd
Glance View
BeiGene Ltd., a global powerhouse in biopharmaceutical innovation, traces its journey back to its roots in Beijing, having established itself with a clear vision—to address the vast unmet needs in cancer treatment. Co-founded by John V. Oyler in 2010, the company set out on a mission to develop effective and accessible therapies for cancer patients worldwide. Operating at the intersection of cutting-edge science and global entrepreneurship, BeiGene built its reputation by investing heavily in research and development. The crux of its model hinges on leveraging both in-house capabilities and strategic collaborations. This has allowed it to expedite the development of a rich pipeline of oncology therapies, with a focus on small molecule drugs and monoclonal antibodies, navigating the complex world of biotechnology to bring pioneering solutions to market. Central to BeiGene's financial engine is its adeptness at creating a portfolio of marketable cancer therapies, primarily through licensing agreements and strategic partnerships. The company's business model thrives on advancements like Brukinsa, a treatment for certain types of lymphoma, which has seen significant regulatory approvals worldwide. Partnerships with pharmaceutical giants, such as Amgen, have amplified its global reach, enabling it to widen its distribution network beyond China to North America and Europe. By embedding itself into various markets and healthcare systems, BeiGene captures revenue through product sales, milestone payments, royalties, and collaboration fees. This multifaceted approach not only spearheads its growth trajectory but also solidifies its reputation as a company committed to combating cancer on a global scale, driven by innovation and an unwavering dedication to its mission.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Beigene Ltd's most recent financial statements, the company has Operating Margin of -7.5%.
You don't have any saved screeners yet